Top Markets
Coin of the day
Impel Pharmaceuticals Inc. Impel Pharmaceuticals Inc.

Impel Pharmaceuticals Inc.

IMPL
Kedudukan dalam Saham #37159
Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical... Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical firm, concentrating its efforts on creating and commercializing therapies for individuals in the United States who are affected by central nervous system (CNS) conditions. Leading its product portfolio is Trudhesa, an innovative upper nasal formulation of dihydroergotamine, specifically engineered for the prompt relief of acute migraine attacks. Furthermore, the company's development pipeline encompasses INP105, another upper nasal medication containing olanzapine, currently being advanced for the rapid treatment of agitation and aggressive behaviors associated with autism spectrum disorder. Impel is also progressing with INP107, an intranasal carbidopa/levodopa compound, which has already successfully concluded its Phase IIa clinical trial aimed at managing "OFF" episodes in Parkinson's disease patients. Initially established in 2008, the company was formerly known as Impel NeuroPharma, Inc. before rebranding to Impel Pharmaceuticals Inc. in April 2022. Its corporate headquarters are situated in Seattle, Washington.
Harga Saham
$0.1011
Disegerakkan terakhir: 2024-01-16
Modal Pasaran
$1.96M
Perubahan (1 hari)
1.10%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Impel Pharmaceuticals Inc. (IMPL)

Kategori

Sejarah harga saham bagi Impel Pharmaceuticals Inc. (IMPL)
Harga penutupan tertinggi: $0.10 pada 2024-01-01

Harga penutupan terendah: $15.09 pada 2021-04-01
Sejarah harga saham Impel Pharmaceuticals Inc. dari 2021 hingga 2026
Prestasi harga saham tahunan
Tahun Prestasi
2024 -63.47%
2023 -91.81%
2022 -64.07%
2021 0.00%
Harga saham bagi syarikat atau pesaing serupa
Syarikat Harga saham Perubahan 1thn% Negara
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE